NEW YORK (Reuters) - Indevus Pharmaceuticals Inc. said on Friday that U.S. regulators approved its experimental drug for overactive bladder.

The U.S. Food and Drug Administration approved the drug, Sanctura, which will be co-promoted by the Croatian drug maker Pliva through its specialty U.S. subsidiary Odyssey Pharmaceuticals Inc. The drug is expected to be launched during the third quarter.

The drug belongs to a class known as muscarinic receptor antagonists, which relax smooth muscle tissue in the bladder and reduce bladder contractions, the cause of overactive bladder.

The drug's main side effects are dry mouth and constipation. It is already marketed in Europe.

Copyright © 2003 Reuters Limited. All rights reserved. Republication or redistribution of Reuters Limited content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters Limited. Reuters Limited shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.